ArticleDiscover oncology2025
CD44 overexpression as a mediator of drug resistance in oral cancer: a meta-analysis unveiling molecular underpinnings and therapeutic implications.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Modulation ofInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTherapeutic resistance in oral cancer, with cancer stem cells (CSCs) playing a pivotal role, remains a major clinical challenge. CD44, a key CSC marker, has been implicated in multidrug resistance mechanisms through drug efflux, DNA repair, and anti-apoptotic pathways. This meta-analysis aims to systematically evaluate the association between CD44 expression and clinicopathological characteristics in oral cancer patients through analysis of controlled clinical studies.
methodsWe systematically searched PubMed, EMBASE, Cochrane Library, Web of Science, CNKI, VIP, WanFang, and China Biomedical Literature Database from inception to September 2022. Controlled clinical studies examining CD44 overexpression in relation to clinicopathological characteristics and survival outcomes in oral cancer patients were included. Quality assessment was performed using the Newcastle-Ottawa Scale. Data were analyzed using RevMan 5.3 software.
resultsTen high-quality studies comprising 846 oral cancer patients were included. CD44 overexpression was significantly associated with advanced local tumor invasion (T category: OR: 1.38; 95% CI 1.14-1.66; P < 0.001; I²=25%). No significant associations were found with N category, histological grade, or vascular invasion. Pooled survival analysis was limited by heterogeneous reporting methods across studies.
conclusionCD44 overexpression serves as a molecular marker of therapeutic resistance in oral cancer, particularly associated with local tumor progression. These findings highlight CD44-targeted therapies as promising strategies to overcome treatment resistance. Future large-scale, multicenter trials are needed to validate CD44 isoforms as prognostic biomarkers and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.